当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Ziang Chen
Minimally invasive surgery has revolutionized the field of surgical oncology by offering patients the benefits of reduced morbidity and shorter recovery times. The introduction of sentinel lymph node biopsy (SLNB) in the context of minimally invasive cancer surgery has further refined the diagnostic and therapeutic approaches for various malignancies. This study aims to critically evaluate the role of SLNB in the realm of minimally invasive cancer surgery, shedding light on its significance, challenges, and outcomes. The use of minimally invasive techniques, such as laparoscopy and robotic-assisted surgery, has gained widespread acceptance in the treatment of various cancers, including breast, melanoma, and gynecological malignancies. These approaches offer patients the advantage of smaller incisions, decreased postoperative pain, and quicker return to normal activities. However, ensuring accurate staging and lymph node assessment remains crucial for optimal cancer management. SLNB has emerged as a pivotal tool in this context. By identifying the sentinel lymph node the first node in the lymphatic basin draining the tumor surgeons can make informed decisions regarding the extent of lymph node dissection and adjuvant therapies. This not only minimizes unnecessary lymph node dissection but also reduces the risk of associated complications, such as lymphedema.